Quick Answer
ENDRA Life Sciences Inc. reported Research And Development Expense of $1.85 million for the year ending 2025.
- ENDRA Life Sciences Inc. showed a decrease of -42.0% in Research And Development Expense from 2024 to 2025.
- This data is from ENDRA Life Sciences Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $198.9 thousand | Q2 2016: $103.6 thousand | Q3 2016: $137.5 thousand | Q1 2017: $95.8 thousand | Q2 2017: $174.7 thousand | Q3 2017: $300.5 thousand | Q1 2018: $1.67 million | Q2 2018: $839.8 thousand | Q3 2018: $1.16 million | Q1 2019: $1.77 million | Q2 2019: $1.30 million | Q3 2019: $1.47 million | Q1 2020: $1.52 million | Q2 2020: $1.49 million | Q3 2020: $1.77 million | Q1 2021: $1.14 million | Q2 2021: $1.74 million | Q3 2021: $1.17 million | Q1 2022: $1.21 million | Q2 2022: $1.85 million | Q3 2022: $1.83 million | Q1 2023: $1.39 million | Q2 2023: $1.40 million | Q3 2023: $1.63 million | Q1 2024: $1.04 million | Q2 2024: $716.4 thousand | Q3 2024: $794.4 thousand | Q3 2025: $432.1 thousand.
- Over the full 10 years of available data (2016 to 2025), ENDRA Life Sciences Inc.'s Research And Development Expense has grown by 273.5%.
- Historical annual values: Fiscal year 2025: $1.85 million | Fiscal year 2024: $3.19 million | Fiscal year 2023: $5.00 million | Fiscal year 2022: $6.55 million | Fiscal year 2021: $5.48 million | Fiscal year 2020: $5.92 million | Fiscal year 2019: $6.57 million | Fiscal year 2018: $4.72 million | Fiscal year 2017: $1.93 million | Fiscal year 2016: $495.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: